Recent Updates
Recently added Catalysts
ARAY Positive Sentiment

The Royal Marsden NHS Foundation Trust: Embracing Technological Advancements in Radiation Therapy

Key Takeaway: The Royal Marsden NHS Foundation Trust has integrated the Radixact Treatment Delivery Systems to enhance its radiation therapy capabilities. This technological advancement allows the hospital to treat approximately 6,000 patients annually with improved efficiency and precision. The successful implementation involved collaboration among various departments and comprehensive training for staff. The hospital aims to expand its treatment offerings further with the new systems.
Price reaction · baseline $1.85 (2024-12-20 close) · hit pre-market · clean, no other ARAY news in the window
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • The Royal Marsden is enhancing patient care with advanced technology.
  • The Radixact System improves treatment efficiency and precision.
  • Collaboration among multidisciplinary teams ensures smooth implementation.
  • Training provided by Accuray equips staff with necessary skills.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~10 mo
Medium dilution risk
Lead asset
5Fluorouracile and Mitomycin-C
Phase 2 · Locally Advanced Anal Canal Cancer

Full Press Release Details

The Royal Marsden , in London, UK, opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer hospital and National Institute for Health and Care Research (NIHR) Biomedical Research Centre for Cancer, working closely with its principal academic partner, the Institute of Cancer Research (ICR). The Royal Marsden and the ICR are ranked in the top five cancer centres in the world for the impact of their research, treating over 59,000 patients every year, including those from the UK’s National Health Service (NHS) and private patients. The Royal Marsden operates from two centres, in Chelsea and Sutton, and also has a Medical Daycare Unit at Kingston Hospital.
We interviewed Therapeutic Radiographer, Shabanaz Boodhoo, Adaptive Workflow Operational Superintendent on her experience with the introduction of the latest Radixact® System to The Royal Marden at the Sutton department.
At The Royal Marsden NHS Foundation Trust, the pursuit of excellence in patient care is paramount. Shabanaz Boodhoo said: “In the Sutton department, the hospital proudly operates six linear accelerators, one MR Linac, one CyberKnife® System, and now has recently acquired two Radixact Treatment Delivery Systems, replacing the two oldest c-arm linear accelerators. These technological advancements enable radiation therapy treatment of approximately 6,000 patients annually.”

Collaborative Efforts for Seamless Implementation

Shabanaz Boodhoo says: “The success of implementing advanced technology is largely due to the strong and collaborative relationship maintained with medical physics and clinical oncology colleagues. The multidisciplinary team (MDT) approach, supported by a comprehensive project plan and regular meetings, has ensured the smooth and timely implementation of these new systems.”

Training and Preparation

“The entire installation process of the first Radixact System, from start to treating the first patient, was a seamless experience. The core team had the privilege of attending training sessions in Switzerland, delivered by Accuray at the Genolier Innovation Hub . The hands-on training was insightful and equipped the team with the knowledge and skills needed to operate the Radixact System in a safe and effective manner,” reports Shabanaz Boodhoo.
At The Royal Marsden NHS Foundation Trust, the pursuit of excellence in patient care is paramount. Shabanaz Boodhoo said: “In the Sutton department, the hospital proudly operates six linear accelerators, one MR Linac, one CyberKnife® System, and now has recently acquired two Radixact Treatment Delivery Systems, replacing the two oldest c-arm linear accelerators. These technological advancements enable radiation therapy treatment of approximately 6,000 patients annually.”

Collaborative Efforts for Seamless Implementation

Shabanaz Boodhoo says: “The success of implementing advanced technology is largely due to the strong and collaborative relationship maintained with medical physics and clinical oncology colleagues. The multidisciplinary team (MDT) approach, supported by a comprehensive project plan and regular meetings, has ensured the smooth and timely implementation of these new systems.”

Training and Preparation

“The entire installation process of the first Radixact System, from start to treating the first patient, was a seamless experience. The core team had the privilege of attending training sessions in Switzerland, delivered by Accuray at the Genolier Innovation Hub . The hands-on training was insightful and equipped the team with the knowledge and skills needed to operate the Radixact System in a safe and effective manner,” reports Shabanaz Boodhoo.

Operational Plans and Future Goals

She goes on to explain how the Radixact System will benefit the radiotherapy department. “The Radixact System stands out as a unique technology compared to conventional linear accelerators (linacs). The treatment workflow is both fast and efficient, and the ClearRT® helical kVCT images produced are of exceptional quality. With three different scanning modes, the team is able to verify patient anatomy and positioning prior to delivering treatment, enhancing precision and safety.”
“Currently, a dedicated team operates the Radixact System, and plans are in place to rotate more staff, ensuring a broader range of expertise and familiarity with the system.”

Go-Live Event and Clinical Focus

“The Go-Live event was a momentous occasion, supported by the Accuray team on-site. The initial focus was on areas that would benefit the most clinically, such as treatments for long pelvic volumes and head and neck tumors. As the second system gets installed next year, additional treatment sites will be explored, ultimately aiming to treat as many patients with the Radixact Systems as with conventional linacs” says Shabanaz.

Delivering Cutting-edge Treatment Options

The hospital is thrilled to incorporate the Radixact System, the latest generation TomoTherapy® platform, into its radiotherapy treatment offerings. This advancement would not have been possible without the generous support of The Royal Marsden Cancer Charity , to whom the hospital is deeply grateful. The addition of the Radixact System is a significant step forward in the commitment to delivering cutting-edge treatment options for patients’ benefit.
Stay tuned for more updates as capabilities continue to be enhanced, providing the highest standard of care.
The views contained and expressed in this blog, are those of the author and do not necessarily reflect the views or policies of Accuray Incorporated or its subsidiaries. No official endorsement by Accuray Incorporated or any of its subsidiaries of any vendor, products or services contained in this blog is intended or should be inferred

Frequently Asked Questions

What is the Radixact System?

The Radixact System is an advanced treatment delivery system for radiation therapy.

How many patients does The Royal Marsden treat annually?

The Royal Marsden treats approximately 6,000 patients each year.

What training did staff receive for the Radixact System?

Staff attended training sessions in Switzerland, focusing on safe and effective operation.

What are the benefits of the Radixact System?

The Radixact System offers fast, efficient treatment workflows and high-quality imaging.

Who supported the acquisition of the Radixact System?

The Royal Marsden Cancer Charity provided generous support for the acquisition.

Last updated: Dec 23, 2024